Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

This study is for the treatment of non-small cell lung cancer.

Primary disease category: Cancer

Secondary disease categories: Cancer, Lung Cancer

Sponsor: Southwest Oncology Group

Protocol number: EA5142

Projected enrollment dates: September 2016 to May 2018

Official study title: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers